WallStSmart

Nokia Corp ADR (NOK)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nokia Corp ADR generates 547% more annual revenue ($19.89B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 3.3%. NOK appears more attractively valued with a PEG of 0.83. WST earns a higher WallStSmart Score of 55/100 (C-).

NOK

Hold

46

out of 100

Grade: D+

Growth: 2.7Profit: 4.5Value: 4.7Quality: 7.0
Piotroski: 4/9Altman Z: 1.60

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NOKSignificantly Overvalued (-734.1%)

Margin of Safety

-734.1%

Fair Value

$0.88

Current Price

$8.41

$7.53 premium

UndervaluedFair: $0.88Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NOK3 strengths · Avg: 8.3/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.838/10

Growing faster than its price suggests

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

NOK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
2.4%4/10

2.4% revenue growth

Altman Z-ScoreHealth
1.604/10

Distress zone — elevated risk

Return on EquityProfitability
3.0%3/10

ROE of 3.0% — below average capital efficiency

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NOK

The strongest argument for NOK centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.83 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : NOK

The primary concerns for NOK are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 63.5x leaves little room for execution misses. Thin 3.3% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

NOK profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

NOK generates stronger free cash flow (225M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 46/100), backed by strong 16.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nokia Corp ADR

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Nokia Corporation offers fixed and mobile network solutions globally. The company is headquartered in Espoo, Finland.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?